Drug Profile
AMG 595
Alternative Names: Anti-EGFRvIII-DM1 immunoconjugateLatest Information Update: 14 Feb 2024
Price :
$50
*
At a glance
- Originator Amgen
- Class Antibodies; Antineoplastics; Drug conjugates; Immunotoxins; Maytansinoids; Monoclonal antibodies
- Mechanism of Action Apoptosis stimulants; Immunomodulators; Mitosis inhibitors; Tubulin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anaplastic astrocytoma; Glioblastoma
Most Recent Events
- 12 Feb 2024 ImmunoGen has been acquired by AbbVie
- 16 Jul 2016 No recent reports of development identified for phase-I development in Anaplastic-astrocytoma(Recurrent) in Australia (Parenteral)
- 16 Jul 2016 No recent reports of development identified for phase-I development in Anaplastic-astrocytoma(Recurrent) in USA (Parenteral)